6 курс / Гастроэнтерология / Марченко_Н_В_Клинико_морфологические_и_психоэмоциональные_взаимосвязи
.pdf201
76. Bogdanos, D. P. Autoimmune liver serology: current diagnostic and clinical challenges / D. P. Bogdanos, P. Invernizzi, I. R. Mackay, D. Vergani // World J. Gastroenterol. — 2008. — Vol. 14, № 21. — P. 3374–3387.
77. Carpenter, H. A. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants / H. A. Carpenter, A. J. Czaja // Clin. Liver Dis. — 2002. — Vol. 6, № 3. — P. 685-705.
78.Carswell, E. A. An endotoxin-induced serum factor that causes necrosis of
tumors |
/ E. A.Carswell, L. J. Old, R. L. Kassel [et al.] // Proc. Natl. Acad. Sci. |
U. S. A. — 1975. — Vol. 72, № 9. — P. 3666–3670. |
|
79. |
Carta, M. G. Association of chronic hepatitis C with recurrent brief depression / |
M. G. Carta, J. Angst , M. F. Moro [et al.] // J. Affect. Disord. — 2012. — Vol. 141,
№ 2-3. — P. 361-366.
80.Chazouilleres, O. Primary biliary cirrhosis — autoimmune hepatitis overlap syndrome: clinical features and response to therapy / O. Chazouilleres, D. Wendum, L. Serfaty, S. Montembault [et al.] // J. Hepatol. — 1998. — Vol. 28. № 2. — P. 296–301.
81.Chazouillères, O. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome / O. Chazouillères, D. Wendum, L. Serfaty [et al.] // J. Hepatol. — 2006. — Vol. 44, № 2. — P. 400-406.
82.Chen, R. Meta-Analysis: The Relationship between TNF-Alpha Polymorphisms and Susceptibility to Primary Biliary Cirrhosis / R. Chen, X. Cai, Z. Han [et al.] // Hepatogastroenterology. — 2013. — Vol. 60, № 123. — P. 568-576.
83.Chen, C. H. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C / C. H. Chen, C. M. Lee, Chen C. H. [et al.] // Chang Gung Med. J. — 2010. — Vol. 33, № 3. — P. 258-265.
84.Cohen, S. M. Autoimmune hepatitis associated with the use of black cohosh: a case study / S. M. Cohen, A. M. O'Connor, J. Hart [et al.] // Menopause. — 2004. —
Vol. 11, № 5. — P. 575–577.
85.Cook, G. C. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis / G. C. Cook, R. Mulligan, S. Sherlock // Q. J. Med. — 1971. — Vol.
40, № 158. — P. 159–185.
202
86. Cookson, S. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis / S. Cookson, P. K. Constantini, M. Clare [et al.] // Hepatology.
— 1999. — №. 30. — P. 851-856.
87.Corpechot, C. Biochemical markers of liver fibrosis and lymphocyticpiecemeal
necrosis in UDCA-treated patients with primary biliary cirrhosis / C. Corpechot, A. Poujol-Robert, D. Wendum [et al.] // Liver Int. — 2004. — Vol. 24, № 3. — P. 187– 193.
88. Corruble, E. Depressive symptoms predict long-term mortality after liver transplantation / E. Corruble, C. Barry, I. Varescon [et al.] // J. Psychosom. Res. — 2011. – Vol. 71, № 1. — P. 32-37.
89. Cotler, S. J. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy / S. J. Cotler, S. Jakate, D. M. Jensen // J. Clin Gastroenterol. — 2001. — Vol.
32, № 5. — P. 428–430.
90.Cowling, D. C. Lupoid hepatitis / D. C. Cowling, I. R. Mackay, L. I. Taft // Lancet. — 1956. — Vol. 271, № 6957. — P. 1323–1326.
91.Czaja, A. J. Validation of a scoring system for the diagnosis of autoimmune hepatitis / A. J. Czaja, H. A. Carpenter // Dig. Dis. Sci. — 1996. — Vol. 41, № 2. — P. 305–314.
92.Czaja, A. J. Autoantibodies as prognostic markers in autoimmune liver disease /
A. J. Czaja // Dig. Dis. Sci. ― 2010. ― Vol. 55, № 8. ― Р. 2144–2161.
93. Czaja, A. J. Autoimmune hepatitis with incidental histologic features of bile duct injury / A. J. Czaja, H. A. Carpenter // Hepatol. — 2001. — Vol. 34, № 4, Pt 1. —
P. 659–665.
94.Czaja, A. J. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis / A. J. Czaja, S. Cookson, P. K. Constantini [et al.] // Gastroenterology. — 1999. — № 117. — P. 645-652.
95.Czaja, A. J. Diagnosis and management of the overlap syndromes of autoimmune hepatitis / A. J. Czaja // Can. J. Gastroenterol. — 2013. — Vol. 27, № 7.
— P. 417-423.
203
96. Czaja, A. J. Diagnosis and treatment of autoimmune hepatitis / A. J. Czaja, D. K. Freese, American Association for the Study of Liver Disease // Hepatol. — 2002.
— Vol. 36, № 2. — P. 479–497.
97.Czaja, A. J. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis / A. J. Czaja, H. A. Carpenter // J. Hepatol. — 2004. — Vol. 40, № 4. — P. 646-652.
98.Czaja, A. J. Autoantibodies in liver disease / A. J. Czaja, H. A. Homburger // Gastroenterology. — 2001. — Vol. 120, № 1. — P. 239-249.
99.Czaja, A. J. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis / A. J. Czaja, M. P. Manns // Gastroenterology. — 2010. —
Vol. 139, № 1. — P. 58-72.
100. Czaja, A. J. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis / A. J. Czaja, P. Muratori, L. Muratori [et al.] // Liver Int. — 2004. — Vol. 24, № 4. — P. 322–329.
101.Czaja, A. J. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States / A. J. Czaja, E. O. Souto, P. L. Bittencourt [et al.] // J. Hepatol. — 2002. — Vol. 37, № 3. — P. 302–308.
102.Czaja, A. J. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis / A. J. Czaja, M. D. J. Strettell, L. J. Thomson [et al.] // Hepatol. — 1997. — Vol. 25, № 2. — P. 317–323.
103.Delgado, J. The epidemiology of primary biliary cirrhosis in southern Israel /J. Delgado, A. D. Sperber, V. Novack [et al.] // Isr. Med. Assoc. J. — 2005. Vol. 7, № 11.
— P. 717-721.
104.Desmet, V. J. Classification of chronic hepatitis: diagnosis, grading and staging / V. J. Desmet, M. Gerber, J. H. Hoofnagle [et al.] // Hepatol. — 1994. — Vol. 19, № 6.
— P. 1513–1520.
105.Devin, A. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation / A. Devin, A. Cook, Y. Lin [et al.] // Immunity. —2000. — Vol. 12, № 4. — P. 419-429.
204
106.Donaldson, P. T. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study / P. T. Donaldson, A. Baragiotta, M. A. Heneghan [et al.] // Hepatology. — 2006. — Vol. 44, № 3. — P. 667-674.
107.Douglas, L. N. Primary Biliary Cirrhosis / L. N. Douglas, D. J. Brian, N. Konstantinos // Best Pract. Res. Clin. Gastroenterol. — 2010. — Vol. 24, № 5. —
P. 647–654.
108. Dowlati, Y. A meta-analysis of cytokines in major depression / Y. Dowlati, N. Herrmann, W. Swardfager [et al.] // Biol. Psychiatry. — 2010. — Vol.
67, № 5. — P. 446-457.
109.Du, Y. J. Sputum interleukin-6, tumor necrosis factor-α and Salivary cortisol as
new biomarkers of depression in lung cancer patients / Y. J. Du, H. Y. Zhang, B. Li [et al.] // Prog. Neuropsychopharmacol. Biol. Psychiatry. — 2013. — Vol. 47. — P. 69-76.
110.Duivis, H. E. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA) / H. E. Duivis, N. Vogelzangs, N. Kupper [et al.] // Psychoneuroendocrinology. — 2013. — Vol. 38, № 9. — P. 1573-1585.
111.Dumoulin, F.L. Intrahepatic Expression of Interleukin-1b and Tumor Necrosis Factor–a in Chronic Hepatitis C / F.L. Dumoulin, L. Leifeld, U. Honecker [et al.] // J. Infect. Dis. — 1999. — Vol. 180, № 5. — P. 1704-1708.
112.Durazzo, M. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? / M. Durazzo, G. Niro, A. Premoli [et al.] // J. Gastroenterol. — 2009. — Vol. 44, № 5. — P. 476-482.
113.EASL Clinical Practice Guidelines. Management of cholestatic liver diseases / EASL // J. Hepatol. — 2009. — Vol. 51, № 2. — P. 237–267.
114.Efe, C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? / C. Efe // Autoimmun. Rev. — 2013. — Vol. 12, № 3. — P. 337-
115.Efe, C. Anti TNF-alpha therapy can be a novel treatment option in patients with autoimmune hepatitis / C. Efe, T. Purnak, E. Ozaslan // Aliment. Pharmacol. Ther. —
2010. — Vol. 32, № 1. — P. 115.
205
116.Ermolaeva M.A., Michallet M.C., Papadopoulou N. et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses / M.A. Ermolaeva, M.C. Michallet, N. Papadopoulou [et al.] // Nat Immunol. – 2008. – Vol. 9, № 9. – P. 1037-1046.
117.Estradas, J. Autoimmune hepatitis with giant-cell transformation / Estradas J., Pascual-Ramos V., Martínez B, [et al.] // Ann. Hepatol. — 2009. — Vol. 8, № 1. — P. 68-70.
118.Fallatah, H. I. Autoimmune Hepatitis as a Unique Form of an Autoimmune Liver Disease: Immunological Aspects and Clinical Overview [Электронный ресурс] /
H. I. Fallatah, H O. Akbar // Autoimmune Dis. — 2012. Режим доступа:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530748/
119.Fallatah, H. I. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia / H. I. Fallatah, H. O. Akbar, Y. A. Qari // Saudi. J. Gastroenterol. — 2010. — Vol. 16, № 2. — P. 95-99.
120.Fan L.Y., Zhong R.Q., Tu X.Q. et al. Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population // Zhonghua Gan Zang Bing Za Zhi. – 2004.– V. 12, N. 3. – P. 160-162.
121.Feldmann, M. TNF alpha is an effective therapeutic target for rheumatoid arthritis / M. Feldmann, F. M. Brennan, M. J. Elliott [et al.] // Ann. N. Y. Acad. Sci. —
1995. — Vol. 766. — P. 272–278.
122.Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis / M. Feldmann // Nat. Rev. Immunol. — 2002. — Vol. 2. — P. 364–371.
123.Ferrel, L. D. Liver Pathology / L. D. Ferrel, S. Kakar. — Demos Medical Publishing, 2011. — P. 117–119.
124.Floreani, A. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study / A. Floreani, G. Niro, E. Rosa Rizzotto [et al.] // Aliment. Pharmacol. Ther. — 2006. — Vol. 24, № 7. — P. 1051-1057.
125.Forton, D. M. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood
206
manganese levels / D. M. Forton, N. Patel, M. Prince [et al.] // Gut. — 2004. —Vol. 53.
— P. 587–592.
126. Francque, S. Epidemiology and treatment of autoimmune Hepatitis / S. Francque, L. Vonghia, A. Ramon, P. Michielsen // Hepat. Med. — 2012. — № 4. —
P. 1-10.
127. Friedrich-Rust, M. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers / M. Friedrich-Rust, C. Müller,
A. Winckler [et al.] // J. Clin. Gastroenterol. ―2010. ―V. 44, №1. ―58-65.
128.Gajdusek, D. C. An autoimmune reaction against human tissue antigens in certain acute and chronic diseases. I. Serological investigations / D. C. Gajdusek // AMA Arch. Intern. Med. — 1958. — Vol. 101, № 1. — P. 9–29.
129.Gallegos-Orozco, J. F. Health-related quality of life and depression in patients with chronic hepatitis C / J. F. Gallegos-Orozco, A. P. Fuentes, A. J. Gerardo // Arch. Med. Res. — 2003. — Vol. 34, № 2. — P. 124-129.
130.Gershwin, M. E. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients / Gershwin M. E., Selmi C., Worman H. J. // Hepatology. — 2005. — Vol. 42, № 5. — P. 1194-1202.
131.Giroir, B.P. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia / B.P. Giroir, J.H. Johnson, T. Brown [et al.] // J. Clin. Invest. — 1992. —
№. 90. — P. 693–698.
132.Goldblatt, J. The true impact of fatigue in primary biliary cirrhosis: a population study / J. Goldblatt, P. J. Taylor, T. Lipman [et al.] // Gastroenterology. — 2002. —
Vol. 122. — P. 1235–1241.
133.Gordon, M. A. Primary biliary cirrhosis shows association with genetic
polymorphism of tumour necrosis factor alpha promoter region / M. A. Gordon, E. Oppenheim, N. J. Camp [et al.] // Journal of hepatology. — 1999. — Vol. 31, № 2.
— P. 242–247.
134. Ghabril, M. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases / M. Ghabril, H. L. Bonkovsky, C. Kum [et al.] // Clin. Gastroenterol. Hepatol. — 2013. — Vol. 11, №. 5. — P. 558-564.
207
135.Graham, A. M. Bile duct cells in primary biliary cirrhosis are 'primed' for apoptosis / A. M. Graham, M. M. Dollinger, S. E. Howie, D. J. Harrison // Eur. J. Gastroenterol. Hepatol. — 1998. — Vol. 10, № 7. — P. 553-557.
136.Granito, A. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis/ A Granito., P. Muratori, L. C. Quarneti [et al.] // Expert. Rev. Mol. Diagn. —
2012. — Vol. 12, № 1. — P.65–74.
137. Grivennikov, S. I. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects / S. I. Grivennikov, A. V. Tumanov, D. J. Liepinsh [et al.] // Immunity. — 2005.
— Vol. 22, № 1. — P. 93-104.
138.Hanada S. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes / S. Hanada, M. Harada, H. Koga [et al.] // Liver Int. — 2003. — Vol. 23, № 1. — P. 3-11.
139.Harada K. A case of autoimmune hepatitits exacerbated by the
administration of etanercept in the patients with rheumatoid arthritis / K. Harada, Y. Akai, S. Koyama [et al.] // Clin. Rheumatol. — 2008. — Vol. 27, № 8. —
P. 1063-1066.
140. Harashima, S. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells / S. Harashima, T. Horiuchi, N. Hatta [et al.] // J. Immunol. — 2001. — Vol. 166, № 1. —
P. 130-136.
141.Heathcote, E. J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines / E. J. Heathcote // Hepatol. — 2000. — Vol. 31, № 4. — P 1005–1013.
142.Hale, M. Fatigue in primary biliary cirrhosis [Электронный ресурс] / M. Hale,
J. L. Newton, D. E. Jones // BMJ. — 2012. Режим доступа: http://www.bmj.com/content/345/bmj.e7004.long
143. Hemminki, K. Subsequent autoimmune or related disease in asthma patients: clustering of diseases or medical care? / K. Hemminki, X. Li, J. Sundquist, K. Sundquist // Ann. Epidemiol. ― 2010. ― Vol. 20, № 3. ― P. 217–222.
208
144. Hennes, E. M. Simplified criteria for the diagnosis of autoimmune hepatitis / E. M. Hennes, M. Zeniya, A. J. Czaja [et al.] // Hepatol. — 2008. — Vol. 48, № 1. —
P. 169–176.
145.Heurgué, A. Overlap syndrome of primary biliary cirrhosis and autoimmune
hepatitis: a retrospective study of 115 cases A. Heurgué, F. Vitry, M. D. Diebold // Gastroenterol.
№ 1. — P. 17-25.
of autoimmune liver disease / Clin. Biol. — 2007. — Vol. 31,
146.Himoto, T. Clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody / T. Himoto, M. Murota, H. Yoneyama // Hepatol. Res. — 2010. — Vol. 40, № 8. — P. 786-792.
147.Hirschfield, G. M. Diagnosis of primary biliary cirrhosis / G. M. Hirschfield // Best Pract. Res. Clin. Gastroenterol. — 2011. — Vol. 25, № 6. — P. 701-712.
148.Hirschfield, G. M. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants / G. M. Hirschfield, X. Liu, C. Xu [et al.] // N. Engl. J. Med. — 2009.
— Vol. 360, № 24. — P. 2544-2555.
149.Hohenester, S. Primary biliary cirrhosis / S. Hohenester, R. P. OudeElferink, U. Beuers // Semin. Immunopathol. — 2009. — Vol. 31, № 3. — P. 283-307.
150.Howel, D. An exploratory population-based case-control study of primary biliary cirrhosis / D. Howel, C. M. Fischbacher, R. S. Bhopal // Hepatology. — 2000. —
Vol. 31, № 5ю — P. 1055-10 60.
151.Hsu, H. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways / H. Hsu, H.B. Shu, M.G. Pan, D.V. Goeddel // Cell. — 1996. — Vol. 84, № 2. — P. 299-308.
152.Hübscher, S. G. Histological classification of autoimmune cholestatic liver diseases. In: Immunology and Liver / M. P. Manns, G. Paumgartner, U. Leuschner (Hrsg.) // Kluwer Academic Publishers, Dordrecht, Boston, London. — 2000. —
P. 223-243.
153. Huet, P. M. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis / P. M. Huet, J. Deslauriers, A. Tran, C. [et al.] // Am. J. Gastroenterol.
— 2000. — Vol. 95, № 3. — P. 760-767.
209
154. Hurlburt, K. J. Prevalence of autoimmune liver disease in Alaska Natives / K. J. Hurlburt, B. J. McMahon, H. Deubner [et al.] // Am. J. Gastroenterol. — 2002. — Vol.
97, № 9. — P. 2402-2407.
155.Hussain, M. J. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease / M.J. Hussain, A. Mustafa, H. Gallati [et al.] // J. Hepatol. — 1994. — Vol. 21, № 5. — P. 816-821.
156.Imam, M. H. Pathogenesis and management of pruritus in cholestatic liver disease / M. H. Imam, A. A. Gossard, E. Sinakos, K. D. Lindor // J. Gastroenterol. Hepatol. — 2012. — Vol. 27, № 7. — P. 1150-1158.
157.Inoue, M. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling / M. Inoue, M. H. Rashid, R. Fujita // Nat. Med. — 2004. — Vol. 10, № 7. —
P. 712-718.
158.Invernizzi, P. Antinuclear antibodies in primary biliary cirrhosis / P. Invernizzi, C. Selmi, C. Ranftler [et al.] // Semin. Liver Dis. — 2005. — Vol. 25, № 3. — P. 298-
159.Ishak, K. Histological grading and staging of chronic hepatitis / K. Ishak, A. Baptista, L. Bianchi [et al.] // J. Hepatol. — 1995. — Vol. 22, № 6. — P. 696-699.
160.Iwamoto, S. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression / S. Iwamoto, M. Kido, N. Aoki [et al.] // Clin. Immunol. — 2013. — Vol. 146, № 1. — P. 15-25.
161.Iwata, M. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis / M. Iwata, K. Harada, N. Kono [et al.] // Hum. Pathol. — 2000. — Vol. 31, № 2. — P. 179-184.
162.Jampana, S. C. Pathogenesis of alcoholic hepatitis: Role of inflammatory signaling and oxidative stress / S.C. Jampana, R. Khan // World J. Hepatol. — 2011. —
Vol. 3, № 5. — P. 114-117.
163. Jeng, J. E. Tumor necrosis factor alpha 308.2 polymorphism is
associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma /
210
J.E. Jeng, J.F. Tsai, L.Y. Chuang [et al.] // Neoplasia. — 2007. — Vol. 9, № 11. —
P. 987-992.
164. Jin, P. Expression and significance of interleukin-18, 12 and tumor necrosis factor-α in intrahepaticcholestasis of pregnancy / P. Jin, Y. Shao // Zhonghua Fu. Chan. Ke. Za. Zhi. — 2011. — Vol. 46, № 5. — P. 329-332.
165.Jones, D. E. Pathogenesis of primary biliary cirrhosis / D. E. Jones // Gut. —
2007. — Vol. 56, № 11. — P. 1615-1624.
166.Jones, D. E. Genetic factors in the pathogenesis of primary biliary cirrhosis / D. E. Jones, P. T. Donaldson // Clin. Liver Dis. — 2003. — Vol. 7, № 4 — P. 841–864.
167.Jones, A. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease / A. Jones, P.J. Selby, C. Viner [et al.] // Gut. – 1990. – Vol. 31, № 8. – P. 938-939.
168.Jones, D. E. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis / D.E. Jones, F.E. Watt, J. Grove [et al.] // J. Hepatol. — 1999. — Vol.
30, № 2. — P. 232-236.
169. Kaech, C. Coxiella burnetii as a possible cause of autoimmune liver disease: a case report / C. Kaech, I. Pache, D. Raoult, G. Greub // J. Med. Case Rep. — 2009. — Vol. 3. — P. 8870.
170.Kakumu, S. Production of tumor necrosis factor, interleukin 1, and interferongamma by peripheral blood mononuclear cells from patients with primary biliary cirrhosis / S. Kakumu, K. Yoshioka, Y. Tsutsumi [et al.] // Clin. Immunol. Immunopathol. — 1990. — Vol. 56, № 1. — P. 54-65.
171.Kammer, A. R. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition / A. R. Kammer, S. H. Van der Burg // J. Exp. Med. — 1999. — Vol. 190, № 2. — P. 169-176.
172.Kaneko, J. Long-term outcome of living donor liver transplantation for primary biliary cirrhosis / J. Kaneko, Y. Sugawara, S. Tamura [et al.] // Transpl. Int. — 2012. —
Vol. 25, № 1. — P. 7-12.
173.Kanzler, S. Prese nce of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome) / S.